Researchers have identified an antibody, GT103, that is linked to better outcomes in some lung cancer patients and are testing it as an experimental drug through Grid Therapeutics, a company started by Dr. Edward Patz after years of research at Duke. Patz identified GT103 by studying stored serum from patients